SliTrk5 also has been identified affecting the molecular or clinical phenotypes of gastric cancer (GC) with TP53 mutation [53] and correlating with the radioresistance of nasopharyngeal carcinoma and the prognosis of lung squamous cell carcinoma (Table 1) [54, 55]. Here, SLITRK5 is linked to nasopharyngeal carcinoma.